Investors anticipate a faster decline in the company's revenue, despite its history of growth. The forecasted negative growth is disappointing and is weighing down the shares. A drastic rise in stock price seems unlikely without a material change.
The company's underperformance over the past year may signal unresolved issues. Investors should prioritize high-quality businesses, even during market downturns. Future earnings will be key for current shareholders' profitability.
$Methode Electronics(MEI.US)$Methode Electronics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Dimensional Fund Advisors LP(5.4%)
With Methode Electronics' revenue performance expected to worsen, the P/S ratio remains low. Despite low P/S ratios often suggesting value, the lack of signs of improvement casts doubt on whether the P/S ratio has reached rock bottom, pointing to potential further drops in stock prices.
Despite falling EPS, the situation could've been worse. Methode Electronics' dwindling revenue, earnings, and significant insider buying send mixed signals. Further research advised for serious investors.
Methode Electronics股票討論區
2007年上市的美國公司,主要做遠程控制,電子,無線和傳感器業務。
5年來營收持續增長,營業利潤受毛利率下滑費佔比提升影響除2020年外下滑了4年,淨利潤受其它非經營收入影響近3年持續大幅下滑。毛利率近5年從26.6%下降到22.4%,淨資產收益率從2020年16.8%高點下降到8.3%。
2024年前3季度營收萎縮4.7%,營業利潤受毛利率下滑費佔比提升影響大幅萎縮92.7%,淨利潤受資本性資產減值影響大幅虧損0.66億。
目前市盈率6,考慮到目前業務仍無好轉跡象,暫時觀望。
Most anticipated earnings and economic releases for the coming week, June 19th 23’
...
專欄Today's pre-market stock movers: HTZ, SNOW, MRNA, BP and more
• $MorphoSys(MOR.US)$ +7.9% (entered into equity participation and license agreements for felzartamab and MOR210)
• $Day One Biopharmaceuticals(DAWN.US)$ +7.4% (prices offering of 10 mln shares of common stock at $15.00 per share)
• $赫茲租車(HTZ.US)$ +6.1% (authorizes new $2.0 bln share repurchase program)
• $EverCommerce(EVCM.US)$ +3.6% (announces $50 million share repurchase program)
• $Sprinklr(CXM.US)$ +3.6% (In ...
暫無評論